What is Bio-Rad Laboratories, Inc.'s revenue?

Bio-Rad Laboratories, Inc. (BIO.B) generated $2.6B in revenue over the trailing twelve months, up 1.9% year over year.

Is Bio-Rad Laboratories, Inc. profitable?

Bio-Rad Laboratories, Inc. reported $168.8M in net income over the trailing twelve months, a 6.5% net margin.

What are Bio-Rad Laboratories, Inc.'s profit margins?

Gross margin is 51.9% and operating margin is 8.8%, with a 6.5% net margin.

What is Bio-Rad Laboratories, Inc.'s earnings per share?

Bio-Rad Laboratories, Inc.'s diluted EPS over the trailing twelve months is $5.81.

Where does Bio-Rad Laboratories, Inc.'s income statement data come from?

Every line is extracted from Bio-Rad Laboratories, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Bio-Rad Laboratories, Inc. BIO.B Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$2.58B+0.7%	$2.57B-3.9%	$2.67B-4.7%	$2.8B-4.1%
Total cost of revenue	$1.24B+4.7%	$1.19B-4.5%	$1.24B+0.8%	$1.23B-3.9%
Gross profit	$1.34B-2.8%	$1.38B-3.4%	$1.43B-9.0%	$1.57B-4.4%
Gross margin	51.9%-1.9pp	53.7%+0.3pp	53.4%-2.5pp	55.9%-0.2pp
Research and development	$275.6M-6.9%	$295.9M+19.6%	$247.4M-3.7%	$256.9M-1.4%
Selling, general and administrative	$844.3M+3.7%	$814M-3.3%	$841.7M+1.7%	$827.8M-5.6%
Compensation and benefits	——	——	——	——
Occupancy and equipment	——	——	——	——
Operating income	——	$268.9M-20.4%	$337.8M-30.0%	$482.6M-3.5%
Interest expense	$49M+0.2%	$48.9M-1.0%	$49.4M+29.7%	$38.1M+2,356%
Interest income	——	——	——	——
Other income (expense), net	$90.3M0.0%	$90.3M-15.2%	$106.5M+138%	$44.7M+66.9%
Net investment gains (losses)	——	——	——	——
Income before income taxes	$995.5M+142%	-$2.34B—	——	——
Income tax expense	$235.6M+147%	-$498.3M—	——	——
Diluted earnings per share	$27.65+143%	-$65.04-203%	-$21.49+82.3%	-$121.25-186%
Basic earnings per share	$27.67+143%	-$65.00-203%	-$21.46+82.3%	-$121.14-185%
Weighted-average shares, diluted	109.4M-3.3%	113.1M-3.7%	117.5M-1.4%	119.2M-1.3%
Weighted-average shares, basic	109.4M-3.3%	113.1M-3.6%	117.3M-1.7%	119.2M0.0%
Debt and Equity Securities, Unrealized Gain (Loss)	$900.4M+134%	-$2.66B-112%	-$1.25B+75.9%	-$5.19B—
Investment and other income	——	——	——	——
Gain on retained interest in Sandisk	——	——	——	——
Share-based compensation expense related to employee stock plans	——	——	——	——
Additions / (Releases)	——	——	——	——
Accounts Receivable, Allowance for Credit Loss, Writeoff	——	——	——	——
Amortization of capitalized software and acquired intangible assets	——	——	——	——
Stock options excluded as their inclusion would be anti-dilutive (in shares)	——	——	——	——
Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions	——	——	——	——
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	——	——	——	——
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	——	——	——	——
Effect of exchange rate changes on cash, cash equivalents and restricted cash	——	——	——	——
Effective tax rates	——	——	——	——
Gains (losses) - FVO: changes in fair value	——	——	——	——
Finance Lease Cost	——	——	——	——
Finance Lease Interest Payment On Liability	——	——	——	——
Finance Lease Principal Payments	——	——	——	——
Finance Lease Right Of Use Asset Amortization	——	——	——	——
Gain (Loss), Foreign Currency Transaction, before Tax	$6.6M+65.0%	$4M-45.2%	$7.3M+3,550%	$200K+107%
Foreign Currency Transaction Gain Loss Realized	——	——	——	——
Foreign Currency Translation and Other Adjustments	——	——	——	——
Goodwill Period Increase Decrease	——	——	——	——
Income Taxes Paid, Net	$63.4M-36.2%	$99.4M-23.3%	$129.6M-18.1%	$158.3M+17.5%
Increase (Decrease) in Accounts Payable and Other Operating Liabilities	——	——	——	——
Increase (Decrease) in Deferred Income Taxes	——	——	——	——
Increase Decrease In Deferred Liabilities	——	——	——	——
Increase (decrease) in all other liabilities	——	——	——	——
Add - Incremental shares under stock-based compensation plans (in shares)	——	——	——	——
Interest Paid, Excluding Capitalized Interest, Operating Activity	——	——	——	——
Marketable Securities Unrealized Gain Loss	——	——	——	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	-$286.5M-30.9%	-$218.8M+48.6%	-$425.6M—	——
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$189.7M-18.4%	-$160.2M-893%	$20.2M+102%	-$1.21B-51.4%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	$532.2M+16.9%	$455.2M+21.4%	$374.9M+92.8%	$194.4M-71.0%
Noncash Or Part Noncash Acquisition Accounts Receivable Acquired1	——	——	——	——
Leased devices transferred from inventory to property and equipment	——	——	——	——
Noncash Or Part Noncash Acquisition Investments Acquired1	——	——	——	——
Number of reportable segments	——	——	——	——
Operating Lease Payments	——	——	——	——
Operating lease right-of-use assets amortization expense	——	——	——	——
Option Premium Proceeds For Structured Purchases Of Treasury Stock	——	——	——	——
Option premium received for structured purchases of treasury stock	——	——	——	——
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent	——	——	——	——
Unrealized gains (losses) on hedge instruments	——	——	——	——
Foreign currency translation gains (losses)	——	——	——	——
Other comprehensive income (loss)	——	——	——	——
Other comprehensive income/(loss)	——	——	——	——
Net unrealized gains (losses) on securities still held	——	——	——	——
Other Depreciation and Amortization	——	——	——	——
Other Nonoperating Income	——	——	——	——
Other income, net (Note 6)	$90.3M0.0%	$90.3M-15.2%	$106.5M+138%	$44.7M+66.9%
Payments for Repurchase of Common Stock	$295.5M+45.1%	$203.6M-52.5%	$428.7M+98.7%	$215.7M—
Payments to Acquire Investments	$669.3M-47.6%	$1.28B+85.3%	$689M-66.6%	$2.06B+142%
Payments to Acquire Property, Plant, and Equipment	$157.6M-4.8%	$165.6M+5.7%	$156.7M+38.9%	$112.8M-15.7%
Payments To Suppliers And Employees	$2.06B0.0%	$2.06B-8.1%	$2.24B-7.0%	$2.41B+13.2%
Payments for (proceeds from) derivative instruments, operating activities	——	——	——	——
Contractual payments received	$2.66B+4.0%	$2.55B-4.9%	$2.68B-0.6%	$2.7B-6.5%
Proceeds from Issuance of Common Stock	——	——	——	——
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$62M-68.9%	$199.3M-44.8%	$361.3M+1.0%	$357.8M+4.8%
Proceeds From Other Operating Activities	$81M-5.9%	$86.1M-14.0%	$100.1M+47.0%	$68.1M+93.0%
Sale of investments	$793.6M-28.2%	$1.11B+120%	$501.9M-29.1%	$708.2M+66.4%
Dispositions of property, plant, and equipment	——	——	$200K0.0%	$200K+285%
Standard and Extended Product Warranty Accrual, Decrease for Payments	——	——	——	——
Product Warranty Accrual Warranties Issued	——	——	——	——
Gross realized gains (losses)	——	——	——	——
Repayments of Long-Term Debt	$500K+25.0%	$400K-20.0%	$500K0.0%	$500K-83.4%
Revenue Allocation Percent To Lease Elements	——	——	——	——
Revenue From Contract With Customer Excluding Assessed Tax	——	——	——	——
Right Of Use Asset Obtained In Exchange For Operating Lease Liability	——	——	——	——
Issuance of common stock and reissuance of treasury stock under equity incentive plans, net of forfeitures, value	——	——	——	——
Stock Repurchased During Period, Excise Tax, Amount	——	——	——	——
Treasury stock, value, acquired	——	——	——	——
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	——	——	——	——
Value Appreciation Right, Changes in Fair Value, Gain (Loss)	——	——	——	——
EBIT	$1.11B+312%	$268.9M-20.4%	$337.8M-30.0%	$482.6M-3.5%
EBITDA	——	——	——	——
EBIT	$1.11B+312%	$268.9M-20.4%	$337.8M-30.0%	$482.6M-3.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Bio-Rad Laboratories, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bio-Rad Laboratories, Inc.'s revenue?: Bio-Rad Laboratories, Inc. (BIO.B) generated $2.6B in revenue over the trailing twelve months, up 1.9% year over year.
Is Bio-Rad Laboratories, Inc. profitable?: Bio-Rad Laboratories, Inc. reported $168.8M in net income over the trailing twelve months, a 6.5% net margin.
What are Bio-Rad Laboratories, Inc.'s profit margins?: Gross margin is 51.9% and operating margin is 8.8%, with a 6.5% net margin.
What is Bio-Rad Laboratories, Inc.'s earnings per share?: Bio-Rad Laboratories, Inc.'s diluted EPS over the trailing twelve months is $5.81.
Where does Bio-Rad Laboratories, Inc.'s income statement data come from?: Every line is extracted from Bio-Rad Laboratories, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.